Recruitment is underway, with operations expected by mid-2025. LCCI Hyderabad will be Lilly's second capability center in India, after the launch of LCCI Bengaluru in 2016, the company stated. 'Silent ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

Oak Ridge Investments LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 6.2% during the fourth quarter, according to its most recent Form 13F filing with the ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $725.72. According to ...

In this article, we are going to take a look at where Eli Lilly And Co. (NYSE:LLY) stands against other stocks that could split in the near future. Stock splits don’t change how much a company ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose by more than 2% on the day, thanks largely to news from a rival.

This page features the latest news about the Eli Lilly DRC stock. Eli Lilly : Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or ...